Alexandria Real Estate Equities

ARE

Market cap $13.1B

Fourteen of the highest-yielding, 'safer' S&P 500 dividend stocks are currently attractively priced, with free cash flow supporting their payouts. Top ten S&P 500 dividend 'dogs' are projected to deliver 23.93% to 38.57% net gains by October 2026, based on analyst targets. Stocks like CAG, VZ, DOC, BMY, KVUE, CPB, UDR, VTRS, KIM, TFC, KEY, HPQ, T, and RF meet the ideal of dividends from $1K invested exceeding share price.

Alexandria Real Estate generated an 11% return in Q3. It may be starting to turn around its performance. With a 6.3% yield, a 57% payout ratio, and solid AFFO, ARE's dividend security stands out among healthcare REITs despite sector headwinds. I analyzed a catalyst that investors sometimes forget about in ARE: the potential of Big Pharma and Big Biotech.

U.S. equity markets rallied to fresh record-highs this past week as investors leaned into rate cut expectations following a wave of soft employment data and a Federal Government shutdown. For the fourth time since 1995, the federal government entered a partial "shutdown" after the U.S. Senate failed to reach the 60-vote threshold required for passage of appropriations. Defering to experience from prior shutdowns in 2013 (16 days) and in 2018 (35 days), markets largely shrugged off the latest Congressional impasse, with investors still anticipating a timely resolution.

After a career that spanned two decades of experience at Bear Stearns, Lehman Brothers, and Morgan Stanley, I gained an institutional perspective on dividend stock investing.

ARE demonstrates resilience in a challenging life science real estate market, leveraging its mega-campus model and strong tenant relationships. Despite industry headwinds and high vacancy rates, ARE maintains robust leasing activity, positive spreads, and expects year-end occupancy between 91% and 92.5%. Long-term tailwinds, including projected growth in global pharmaceutical sales and AI-driven demand, position ARE for future success despite current market turbulence.

Alexandria Real Estate Equities is rated a 'Buy' for its undervalued price, high 6.3% yield, and strong long-term prospects. ARE's mega-campus strategy, robust tenant base, and critical role in life sciences support resilient cash flows and future growth. Despite recent occupancy pressures, ARE shows signs of recovery with improving leasing activity, a healthy development pipeline, and solid financials.

ARE and Lilly open Lilly Gateway Labs in San Diego, expanding biotech innovation with advanced labs and collaborative space.

PASADENA, Calif. , Sept. 26, 2025 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator, and developer of collaborative Megacampus™ ecosystems in AAA life science innovation cluster locations, today announced the opening of Lilly Gateway Labs San Diego, powered by Alexandria, on the One Alexandria Square Megacampus in Torrey Pines.

Recent economic data has weakened market optimism. Gold has hit record highs, Treasury yields have fallen, and the dollar index continues to deteriorate as investors seek safety. Despite negative economic signals, growth-driven stocks have reached new highs, defying broader market caution.

Highlighting 10 S&P-rated companies with 4-7% yields, focusing on dividend growth, credit quality, and undervaluation. Pfizer, Alexandria RE, NNN REIT, AES Corp, and Bristol Myers are identified as undervalued winners and recommended as buys for income-focused investors.